The company plans to use the proceeds to test its TCR-T cell therapy in patients with MAGE-A4-positive solid tumors.

The firm will use the funds to support clinical trials of its ATR inhibitor alnodesertib and its pol theta inhibitor ART6043.

The recommendation is based on the Phase II/III DEVOTE study testing the higher dose in treatment-naïve patients and those already on the low dose.

A sponsor will have to demonstrate success with "with several consecutive patients with different bespoke therapies" to ...

CTX310 showed promising safety and efficacy in a small Phase I trial, according to data presented at the American Heart ...

Studies of germline genetic testing programs provide a snapshot of challenges at academic and community practices at the NSGC annual meeting.

The agency is establishing a network of care centers to expand access to regenerative medicine beyond regions served by major ...

The UK regulator is creating a new framework for how it will approve rare disease treatments, which it intends to publish in ...

Genetic testing could improve cancer outcomes for patients, but historical research abuses and access issues have slowed ...

At its annual meeting, the society discussed progress it has made in pushing ahead the Access to Genetic Counselor Services ...

The agency is cautioning patients about the risk of serious, possibly fatal, liver injuries and has limited the gene therapy's use to ambulatory patients.

The agency reviewed data from a Phase II study, in which around 21 percent of patients had a complete response to the menin inhibitor.